Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

TCR2 Therapeutics Inc. (TCRR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.2800+0.0300 (+0.92%)
At close: 04:00PM EDT
3.2600 -0.02 (-0.61%)
After hours: 05:19PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.2500
Open3.2300
Bid3.3000 x 1100
Ask3.4000 x 800
Day's Range3.2100 - 3.3700
52 Week Range2.0650 - 19.0300
Volume122,797
Avg. Volume438,185
Market Cap125.363M
Beta (5Y Monthly)1.79
PE Ratio (TTM)N/A
EPS (TTM)-2.4640
Earnings DateMar 09, 2022 - Mar 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.89
  • GlobeNewswire

    TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 46,600 shares of TCR2’s common stock to 2 new non-executive employees. The stock options were granted as an inducement material to the emp

  • GlobeNewswire

    TCR² Therapeutics Appoints Industry and Finance Veteran Eric Sullivan as Chief Financial Officer

    CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the appointment of Eric Sullivan as Chief Financial Officer where he will be responsible for leading all aspects of financial management and capital market strategy as well as overseeing investor relations and select business operations. “We are excited to announce Eric

  • GlobeNewswire

    TCR² Therapeutics to Participate in Two Upcoming Conferences in June

    CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate at two upcoming conferences in June in New York. Alfonso Quintás-Cardama, Chief Medical Officer of TCR2 Therapeutics, will present an update on Company progress at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 2:00PM E

Advertisement
Advertisement